BAIRD CHEMICAL INDUSTRIES, INC. – Trademark Portfolio
Entity Type: 03
BAIRD CHEMICAL INDUSTRIES, INC. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 5 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include BARDAC, BARLOX, BARLENE, BARQUAT, and BARCHLOR. The owner is based in FAIR LAWN, NJ.
22-10 ROUTE 208
FAIR LAWN, NJ 07410
Showing of trademarks Trademarks
Trademark Classifications
BAIRD CHEMICAL INDUSTRIES, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does BAIRD CHEMICAL INDUSTRIES, INC. have?
BAIRD CHEMICAL INDUSTRIES, INC. has 6 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 cancelled.
What trademark classes does BAIRD CHEMICAL INDUSTRIES, INC. file in?
BAIRD CHEMICAL INDUSTRIES, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are BAIRD CHEMICAL INDUSTRIES, INC.'s most well-known trademarks?
BAIRD CHEMICAL INDUSTRIES, INC.'s registered trademark portfolio includes well-known marks such as BARDAC, BARLOX, BARLENE, BARQUAT, and BARCHLOR. These are among 5 currently registered trademarks in the portfolio.
What is BAIRD CHEMICAL INDUSTRIES, INC.'s trademark registration success rate?
BAIRD CHEMICAL INDUSTRIES, INC. has a 83% trademark registration rate, with 5 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.